{"id":967503,"date":"2026-05-27T09:30:00","date_gmt":"2026-05-27T13:30:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immp-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-immutep-limited-securities-lawsuit-contact-levi-korsinsky\/"},"modified":"2026-05-27T09:30:00","modified_gmt":"2026-05-27T13:30:00","slug":"immp-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-immutep-limited-securities-lawsuit-contact-levi-korsinsky","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immp-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-immutep-limited-securities-lawsuit-contact-levi-korsinsky\/","title":{"rendered":"IMMP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Immutep Limited Securities Lawsuit – Contact Levi & Korsinsky"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Immutep Projected TACTI-004 Would Deliver a “New Standard of Care” for Lung Cancer Patients. Instead, the Trial Was Stopped for Futility After Enrolling Just Half Its Target, and IMMP Investors Lost $2.28 Per Share.<\/i>\n <\/p>\n

\n NEW YORK<\/span>, May 27, 2026<\/span> \/PRNewswire\/ — Levi & Korsinsky, LLP highlights the contrast between Immutep Limited’s (NASDAQ: IMMP) promises to investors and the results that followed. Shareholders who purchased IMMP American Depositary Receipts between March 24, 2025 and March 12, 2026 and lost money may be entitled to recover damages. Find out if you qualify to recover losses<\/a>\u00a0or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/a>\u00a0or (212) 363-7500.<\/p>\n

\n

\n
\n \"Levi
\n <\/a>\n <\/p>\n<\/p><\/div>\n

IMMP ADRs collapsed approximately 83%, falling from $2.76 to $0.48 per share in a single trading session after the company disclosed that its pivotal TACTI-004 Phase III trial was discontinued for futility. The lead plaintiff deadline is July 6, 2026.<\/p>\n

\n The Promise<\/b>\n <\/p>\n

Throughout the Class Period, Immutep’s leadership projected confidence about TACTI-004’s trajectory. The company characterized the trial as among “the most significant milestones in the Company’s history” and asserted that the efti combination had “the potential to establish a new standard of care” in first-line advanced non-small cell lung cancer. Investigators were told the trial was “on track for key milestones,” enrollment was described as proceeding at a “robust pace,” and prior studies were cited as demonstrating “strong efficacy” and an “excellent safety profile.”<\/p>\n